Creative Planning Increases Holdings in ICU Medical, Inc. (NASDAQ:ICUI)

Creative Planning increased its holdings in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 58.6% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 6,193 shares of the medical instruments supplier’s stock after acquiring an additional 2,287 shares during the period. Creative Planning’s holdings in ICU Medical were worth $1,128,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ICUI. Xponance Inc. boosted its holdings in shares of ICU Medical by 6.0% during the 2nd quarter. Xponance Inc. now owns 1,977 shares of the medical instruments supplier’s stock valued at $235,000 after purchasing an additional 112 shares during the last quarter. CWM LLC increased its stake in ICU Medical by 18.5% in the 2nd quarter. CWM LLC now owns 767 shares of the medical instruments supplier’s stock worth $91,000 after acquiring an additional 120 shares during the last quarter. Hexagon Capital Partners LLC raised its holdings in shares of ICU Medical by 162.7% during the 3rd quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 122 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of ICU Medical by 46.4% during the 1st quarter. Russell Investments Group Ltd. now owns 546 shares of the medical instruments supplier’s stock valued at $59,000 after acquiring an additional 173 shares during the last quarter. Finally, Texas Permanent School Fund Corp grew its holdings in shares of ICU Medical by 1.4% in the first quarter. Texas Permanent School Fund Corp now owns 17,708 shares of the medical instruments supplier’s stock valued at $1,900,000 after purchasing an additional 243 shares in the last quarter. Institutional investors own 96.10% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $178.46, for a total transaction of $2,141,520.00. Following the completion of the sale, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at approximately $18,665,666.78. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other ICU Medical news, VP Daniel Woolson sold 2,502 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $163.22, for a total transaction of $408,376.44. Following the transaction, the vice president now directly owns 13,107 shares in the company, valued at $2,139,324.54. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Vivek Jain sold 12,000 shares of the company’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $178.46, for a total value of $2,141,520.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares of the company’s stock, valued at $18,665,666.78. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 40,552 shares of company stock worth $6,679,322 over the last quarter. Company insiders own 6.70% of the company’s stock.

Wall Street Analyst Weigh In

ICUI has been the topic of a number of recent research reports. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research note on Thursday, October 10th. Jefferies Financial Group assumed coverage on shares of ICU Medical in a report on Monday, October 14th. They issued a “hold” rating and a $183.00 price target for the company. KeyCorp boosted their price objective on ICU Medical from $147.00 to $198.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 15th. Raymond James raised their price objective on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research note on Thursday, September 12th. Finally, StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a report on Thursday, September 12th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $170.25.

ICU Medical Stock Down 2.7 %

Shares of NASDAQ ICUI opened at $170.73 on Friday. ICU Medical, Inc. has a 1 year low of $78.28 and a 1 year high of $188.53. The firm has a 50-day simple moving average of $173.70 and a two-hundred day simple moving average of $136.46. The company has a market cap of $4.17 billion, a P/E ratio of -58.47 and a beta of 0.66. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.41 and a quick ratio of 1.08.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.56. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. The firm had revenue of $596.50 million for the quarter, compared to the consensus estimate of $556.64 million. During the same period in the prior year, the business posted $1.58 earnings per share. The company’s revenue for the quarter was up 8.6% on a year-over-year basis. Research analysts anticipate that ICU Medical, Inc. will post 3.81 earnings per share for the current year.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.